Researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have unveiled an experimental drug that successfully curbed weight gain and protected liver health in mice subjected to a high-sugar, high-fat diet throughout their lives.
The newly developed small-molecule drug, known as CPACC, emerged from a comprehensive effort led by UT Health San Antonio to tackle mitochondrial abnormalities linked to conditions like obesity, diabetes, and cardiovascular disease. CPACC operates by regulating the entry of magnesium into mitochondria, the cell components responsible for energy production and calorie burning.
Madesh Muniswamy, molecular biochemist at UT Health San Antonio and senior author of the study, emphasized, “These findings are the result of several years of work.”
Continue reading… “Experimental Drug Shows Promise in Mitigating Weight Gain and Liver Health Impacts”